• Je něco špatně v tomto záznamu ?

Lamotrigine Drug Interactions in Combination Therapy and the Influence of Therapeutic Drug Monitoring on Clinical Outcomes of Adult Patients

M. Grundmann, B. Koristkova, H. Brozmanova, I. Kacirova,

. 2017 ; 39 (5) : 543-549.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc18024866

BACKGROUND: The aim was to study the impact of therapeutic drug monitoring (TDM) on patients on lamotrigine (LTG) therapy and the evaluation of possible drug interactions, especially in triple antiepileptic drug combinations. METHODS: During the period of 2001-2014, 3118 predose samples were taken from 1137 patients >15 years of age as part of their routine TDM. Drug interactions were evaluated using calculation of LTG clearance (CL). RESULTS: Valproic acid (VPA) decreased LTG CL by 66% in bitherapy, and by 35% and 31% in triple therapy with carbamazepine (CBZ) and phenytoin (PHT), respectively. CBZ and PHT increased LTG CL by 52% and 96% in respective bitherapies but by 88% in triple therapy. Clonazepam, levetiracetam, and topiramate had no effect. The LTG therapeutic range (TR) was exceeded in 1% of cases in monotherapy, and in 4%-5% of cases in combination therapy. Only 54% of results were within the TR during 2001-2005, whereas 60%-62% were within the TR during 2006-2014. Adverse drug reactions (ADRs) were reported in 88 cases and occurred more frequently during TR during 2001-2005. Higher number of supratherapeutic levels in combination therapy led to a 3-fold higher incidence of ADR and poorer seizure control, as seizures occurred more often monthly (2.5%) or a few per year (41%) and fewer patients were seizure free (18%). Seizures occurred more often daily and monthly during the first period and in patients with 3 or 4 drugs in combination. CONCLUSIONS: A significantly higher number of supratherapeutic levels were found in combinations with VPA, despite lower doses of LTG. Hepatic enzyme inducers, such as CBZ and PHT only partially compensated for the inhibitory effect of VPA. Decrease of both the frequency of seizures and the incidence of ADRs after TDM implementation suggests that TDM may have given clinicians the opportunity to achieve more optimal patient treatment.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18024866
003      
CZ-PrNML
005      
20180719091739.0
007      
ta
008      
180709s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1097/FTD.0000000000000433 $2 doi
035    __
$a (PubMed)28682924
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Grundmann, Milan $u *Department of Clinical Pharmacology, Faculty of Medicine, University of Ostrava; and Departments of †Clinical Pharmacology and ‡Laboratory Diagnostics, University Hospital Ostrava, Ostrava, Czech Republic.
245    10
$a Lamotrigine Drug Interactions in Combination Therapy and the Influence of Therapeutic Drug Monitoring on Clinical Outcomes of Adult Patients / $c M. Grundmann, B. Koristkova, H. Brozmanova, I. Kacirova,
520    9_
$a BACKGROUND: The aim was to study the impact of therapeutic drug monitoring (TDM) on patients on lamotrigine (LTG) therapy and the evaluation of possible drug interactions, especially in triple antiepileptic drug combinations. METHODS: During the period of 2001-2014, 3118 predose samples were taken from 1137 patients >15 years of age as part of their routine TDM. Drug interactions were evaluated using calculation of LTG clearance (CL). RESULTS: Valproic acid (VPA) decreased LTG CL by 66% in bitherapy, and by 35% and 31% in triple therapy with carbamazepine (CBZ) and phenytoin (PHT), respectively. CBZ and PHT increased LTG CL by 52% and 96% in respective bitherapies but by 88% in triple therapy. Clonazepam, levetiracetam, and topiramate had no effect. The LTG therapeutic range (TR) was exceeded in 1% of cases in monotherapy, and in 4%-5% of cases in combination therapy. Only 54% of results were within the TR during 2001-2005, whereas 60%-62% were within the TR during 2006-2014. Adverse drug reactions (ADRs) were reported in 88 cases and occurred more frequently during TR during 2001-2005. Higher number of supratherapeutic levels in combination therapy led to a 3-fold higher incidence of ADR and poorer seizure control, as seizures occurred more often monthly (2.5%) or a few per year (41%) and fewer patients were seizure free (18%). Seizures occurred more often daily and monthly during the first period and in patients with 3 or 4 drugs in combination. CONCLUSIONS: A significantly higher number of supratherapeutic levels were found in combinations with VPA, despite lower doses of LTG. Hepatic enzyme inducers, such as CBZ and PHT only partially compensated for the inhibitory effect of VPA. Decrease of both the frequency of seizures and the incidence of ADRs after TDM implementation suggests that TDM may have given clinicians the opportunity to achieve more optimal patient treatment.
650    _2
$a dospělí $7 D000328
650    _2
$a antikonvulziva $x terapeutické užití $7 D000927
650    _2
$a karbamazepin $x terapeutické užití $7 D002220
650    _2
$a klonazepam $x terapeutické užití $7 D002998
650    _2
$a lékové interakce $x fyziologie $7 D004347
650    _2
$a monitorování léčiv $x metody $7 D016903
650    _2
$a kombinovaná farmakoterapie $x metody $7 D004359
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a fruktosa $x analogy a deriváty $x terapeutické užití $7 D005632
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a fenytoin $x terapeutické užití $7 D010672
650    _2
$a piracetam $x analogy a deriváty $x terapeutické užití $7 D010889
650    _2
$a záchvaty $x farmakoterapie $7 D012640
650    _2
$a triaziny $x terapeutické užití $7 D014227
650    _2
$a kyselina valproová $x terapeutické užití $7 D014635
655    _2
$a časopisecké články $7 D016428
700    1_
$a Koristkova, Blanka
700    1_
$a Brozmanova, Hana
700    1_
$a Kacirova, Ivana
773    0_
$w MED00004503 $t Therapeutic drug monitoring $x 1536-3694 $g Roč. 39, č. 5 (2017), s. 543-549
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28682924 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180709 $b ABA008
991    __
$a 20180719092040 $b ABA008
999    __
$a ok $b bmc $g 1316997 $s 1021787
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 39 $c 5 $d 543-549 $i 1536-3694 $m Therapeutic drug monitoring $n Ther Drug Monit $x MED00004503
LZP    __
$a Pubmed-20180709

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...